ADMA Quote, Financials, Valuation and Earnings

Ardelyx has a net margin of 23.44% compared to ADMA Biologics's net margin of -55.52%. ADMA Biologics's return on equity of 79.75% beat Ardelyx's return on equity of -34.68%.

ADMA Biologics has a consensus price target of $29.49, signalling upside risk potential of 59.32%. On the other hand Ardelyx has an analysts' consensus of $10.73 which suggests that it could grow by 138.92%. Given that Ardelyx has higher upside potential than ADMA Biologics, analysts believe Ardelyx is more attractive than ADMA Biologics.

ADMA Biologics has a beta of 0.433, which suggesting that the stock is 56.691% less volatile than S&P 500. In comparison Ardelyx has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.538%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ardelyx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. Ardelyx pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $114.8M, which are larger than Ardelyx quarterly revenues of $74.1M. ADMA Biologics's net income of $26.9M is higher than Ardelyx's net income of -$41.1M. Notably, ADMA Biologics's price-to-earnings ratio is 21.78x while Ardelyx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 9.87x versus 2.94x for Ardelyx. Usually stocks with elevated PS ratios are considered overvalued.

Catalyst Pharmaceuticals has a net margin of 23.44% compared to ADMA Biologics's net margin of 40.12%. ADMA Biologics's return on equity of 79.75% beat Catalyst Pharmaceuticals's return on equity of 29.43%.

ADMA Biologics has a consensus price target of $29.49, signalling upside risk potential of 59.32%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of $34.29 which suggests that it could grow by 57.2%. Given that ADMA Biologics has higher upside potential than Catalyst Pharmaceuticals, analysts believe ADMA Biologics is more attractive than Catalyst Pharmaceuticals.

ADMA Biologics has a beta of 0.433, which suggesting that the stock is 56.691% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.664, suggesting its less volatile than the S&P 500 by 33.579%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $114.8M, which are smaller than Catalyst Pharmaceuticals quarterly revenues of $141.4M. ADMA Biologics's net income of $26.9M is lower than Catalyst Pharmaceuticals's net income of $56.7M. Notably, ADMA Biologics's price-to-earnings ratio is 21.78x while Catalyst Pharmaceuticals's PE ratio is 13.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 9.87x versus 5.13x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Geron has a net margin of 23.44% compared to ADMA Biologics's net margin of -50.09%. ADMA Biologics's return on equity of 79.75% beat Geron's return on equity of -46.58%.

ADMA Biologics has a consensus price target of $29.49, signalling upside risk potential of 59.32%. On the other hand Geron has an analysts' consensus of $3.39 which suggests that it could grow by 156.73%. Given that Geron has higher upside potential than ADMA Biologics, analysts believe Geron is more attractive than ADMA Biologics.

ADMA Biologics has a beta of 0.433, which suggesting that the stock is 56.691% less volatile than S&P 500. In comparison Geron has a beta of 0.645, suggesting its less volatile than the S&P 500 by 35.492%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. Geron pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $114.8M, which are larger than Geron quarterly revenues of $39.6M. ADMA Biologics's net income of $26.9M is higher than Geron's net income of -$19.8M. Notably, ADMA Biologics's price-to-earnings ratio is 21.78x while Geron's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 9.87x versus 7.51x for Geron. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of 23.44% compared to ADMA Biologics's net margin of 4.19%. ADMA Biologics's return on equity of 79.75% beat TG Therapeutics's return on equity of 19.78%.

ADMA Biologics has a consensus price target of $29.49, signalling upside risk potential of 59.32%. On the other hand TG Therapeutics has an analysts' consensus of $40.50 which suggests that it could grow by 9.21%. Given that ADMA Biologics has higher upside potential than TG Therapeutics, analysts believe ADMA Biologics is more attractive than TG Therapeutics.

ADMA Biologics has a beta of 0.433, which suggesting that the stock is 56.691% less volatile than S&P 500. In comparison TG Therapeutics has a beta of 1.913, suggesting its more volatile than the S&P 500 by 91.257%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $114.8M, which are smaller than TG Therapeutics quarterly revenues of $120.9M. ADMA Biologics's net income of $26.9M is higher than TG Therapeutics's net income of $5.1M. Notably, ADMA Biologics's price-to-earnings ratio is 21.78x while TG Therapeutics's PE ratio is 154.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 9.87x versus 15.43x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.